Abstract Purpose: To characterize the expression of sphingosine kinase-1 (SPHK1) in human astrocytomas and to investigate the association between SPHK1 expression and progression of astrocytomas. Experimental Design: The expression of SPHK1in normal human astrocytes, astrocytoma cell lines, and four pairs of matched astrocytoma tissues and their adjacent normal brain tissues were detected by quantitative reverse transcription-PCR and Western blot. In addition, SPHK1protein expression was examined in 243 cases of histologically characterized astrocytomas by immunohistochemistry. Statistical analyses were applied to test for prognostic and diagnostic associations. Results: SPHK1in astrocytoma cell lines was elevated at both mRNA and protein levels, and the SPHK1mRNA and protein were significantly up-regulatedby up to 6.8-and 40-fold, respectively, in primary astrocytomas compared with those in the adjacent noncancerous brain tissues. Immunohistochemical analysis showed that 100 of 243 (41.2%) paraffin-embedded archival astrocytoma biopsies exhibited high expression of SPHK1. Statistical analysis suggested that the up-regulation of SPHK1was significantly correlated with the histologic grade of astrocytoma (P = 0.000) and that patients with high SPHK1level exhibited shorter survival time (P < 0.001). Multivariate analysis revealed that SPHK1up-regulation might be an independent prognostic indicator for the survival of patients with astrocytoma. Conclusions: SPHK1might represent a novel and useful prognostic marker for astrocytoma and play a role during the development and progression of the disease.
Malignant glioma is one of the most aggressive cancers, and the overall prognosis for glioma patients remains poor. Reportedly, there has been no significant improvement in the prognosis of glioma during the period from 1973 to 2001 in United States. The cumulative 1-year survival rate of glioma is only 30%, and the median overall survival time is f53 weeks (1) . One fact behind such a low survival rate is the high degree of invasiveness of glioma, associated with suboptimal therapeutic efficacies of surgery, radiotherapy, or chemotherapy (2 -4) . Astrocytoma, which constitutes 65% to 70% of all gliomas, is the most common primary tumor type of the brain in human. The WHO has recently published current criteria for classification and malignancy grading of astrocytoma as being pilocytic (WHO grade 1), diffuse (WHO grade 2), anaplastic (WHO grade 3), and glioblastoma multiforme (WHO grade 4; ref. 5) . Progression from low-to high-grade astrocytoma is coupled with various molecular alterations. However, the cytogenetic and molecular data on various forms of astrocytomas are still inadequate. It is of great clinical value to further understand the molecular mechanism underlying the progression of astrocytoma and to identify useful early diagnostic markers as well as potential targets for astrocytoma-directed therapies.
Recent studies have suggested that lipogenesis/lipid metabolism has become an emerging area of interest in cancer research. Firstly, the rapid growth of cancer cells consumes energy. Secondly, most critical biological processes involved in cancer development and progression, such as enhanced cell proliferation, survival, migration, angiogenesis, and invasion, are known to be tightly associated with lipid-mediated signaling events (6 -9) . For instance, sphingosine-1-phosphate, a bioactive lipid, acts as an extracellular mediator by binding to five G-protein-coupled receptors, that is, sphingosine-1-phosphate receptors, to regulate a variety of biological functions in Imaging, Diagnosis, Prognosis the cells (10, 11) . Sphingosine-1-phosphate has been identified as a potent tumorigenic and angiogenic agent released from cancer cells into the tumor microenvironment. Thus, the bioactive lipid signaling molecules, such as sphingosine-1-phosphate, have been investigated for their potential use as targets for anticancer strategies (12 -15) .
Sphingosine-1-phosphate is produced via sphingosine phosphorylation, which is catalyzed by sphingosine kinase (SPHK). Two functional SPHK isoenzymes, SPHK1 and SPHK2, have been identified in human thus far (16 -18) . SPHKs could be activated by a variety of cellular stimuli, including tyrosine kinase growth factors, tumor necrosis factor-a, and G-proteincoupled receptor ligands (19 -26) . There has been a considerable body of evidence suggesting that SPHK1 can act as an oncogenic enzyme, as up-regulation of SPHK1 has been implicated in the induction of cell survival and proliferation, inhibition of apoptosis, and promotion of tumor progression in mice (27 -30) . Inhibiting or down-regulating SPHK1 could decrease cell proliferation and arrest the cell cycle in glioblastoma cells and breast cancer cells, and a dominantnegative form of SPHK1 was able to suppress tumor formation in nude mice (31 -33) . Moreover, SPHK1 has been found to be up-regulated in several tumor types, such as glioblastoma multiform, intestinal adenoma, acute erythroleukemia, prostate cancer, and colon cancer (33 -37) . However, the clinical and functional significance of SPHK1 expression has not been characterized previously in most grades of human astrocytomas despite that SPHK1 mRNA expression was recently reported to correlate with the poor survival of patients with glioblastoma multiform, the highest grade astrocytoma (WHO grade 4; ref. 33 ).
In the present study, for the first time, we characterized the SPHK1 expression in all forms of astrocytomas from low-to high-WHO grades. We found that the expression level of SPHK1 was strongly correlated with the histologic staging and with the survival time of astrocytoma patients. In addition, the usefulness of SPHK1 as a prognostic factor was assessed in our study by multivariate analysis. Our data suggested that SPHK1 could be an astrocytoma-associated molecule with a prognostic value.
Materials and Methods
Cell lines. Primary normal human astrocytes, isolated from human brain (cerebral cortex) and characterized with immunofluorescence using antibody against glial fibrillary acidic protein, were purchased from the Sciencell Research Laboratories and cultured under the condition as the manufacturer instructed. Astrocytoma cell lines, including U87MG, LN-235, LN-382, LN-444, LN-464, T98G, A172, and SNB19, were kindly provided by Dr. Shi-Yuan Cheng (Department of Pathology, University of Pittsburg) and grown in the DMEM supplemented with 10% fetal bovine serum.
Patients and tissue specimens. This study was conducted on a total of 243 paraffin-embedded astrocytoma specimens, which were histopathologically diagnosed at the First Affiliated Hospital of Sun Yat-Sen University from 2000 to 2005. For the use of these clinical materials for research purposes, prior patient's consents and approval from the 
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Institutional Research Ethics Committee were obtained. Clinical information of the samples is described in detail in Table 1 . Percentage tumor purity in sections adjacent to the regions used for RNA extraction was estimated during routine histopathologic analysis. Normal brain tissues were obtained by collecting donations from individuals who died in traffic accidents and confirmed to be free of any prior pathologically detectable conditions.
RNA extraction, reverse transcription, and real-time reverse transcription-PCR. Total RNA from cultured cells and surgically dissected tumor tissues was extracted using the Trizol reagent (Invitrogen) according to the manufacturer's instruction. The RNA was pretreated with RNase-free DNase (Promega), and 2 Ag RNA was used for cDNA synthesis primed with random hexamers. For PCR amplification of SPHK1, an initial amplification using SPHK1-specific primers was done with a denaturation step at 95jC for 10 min followed by 28 cycles of denaturation at 95jC for 1 min, primer annealing at 55jC for 30 s, and primer extension at 72jC for 30 s. On completion of the cycling steps, a final extension at 72jC for 5 min was done before the reaction was stopped and stored at 4jC. The following primers were used for the amplification of SPHK1 cDNA: forward primer 5 ¶-CCGACGAG-GACTTTGTGCTAGT-3 ¶ and reverse primer 5 ¶-GCCTGTCCCCCC-AAAGCATAGC-3 ¶. Amplification of the h-actin gene was done to serve as an internal control for cDNA loading using primers 5 ¶-GCTCCTCCTGAGCGCAAG-3 ¶ (forward) and 5 ¶-CATCTGCTG-GAAGGTGGACA-3 ¶ (reverse). Real-time reverse transcription-PCR (RT-PCR) was employed to quantify the change of SPHK1 mRNA level in malignant astrocytoma cell lines compared with that in normal human astrocytes as well as in paired primary brain astrocytoma and normal brain tissues. Real-time RT-PCR primers and probes for SPHK1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were designed with the assistance of the Primer Express version 2.0 software (Applied Biosystems). Sequences of the primers are SPHK1 forward primer 5 ¶-CTTGCAGCTCTTCCGGAGTC-3 ¶, SPHK1 reverse primer 5 ¶-GCTCAGTGAGCATCAGCGTG-3 ¶, SPHK1 probe 5 ¶-(FAM) CCCTTTTGGCTGAGGCTGAAATCTCC (TAMRA)-3 ¶, GAPDH forward primer 5 ¶-GACTCATGACCACAGTCCATGC-3 ¶, GAPDH reverse primer 5 ¶-AGAGGCAGGGATGATGTTCTG-3 ¶, and GAPDH probe 5 ¶-(FAM) CATCACTGCCACCCAGAAGACTGTG (TAMRA)-3 ¶. Expression data were normalized to the housekeeping gene GAPDH as a loading control.
Western blotting. Cells were harvested in sampling buffer [62.5 mmol/L Tris-HCl (pH 6.8), 10% glycerol, and 2% SDS] and boiled for 5 min. Protein concentration was determined with the Bradford assay (Bio-Rad Laboratories). Equal amounts of protein were separated Research.
on July 9, 2017. © 2008 American Association for Cancer clincancerres.aacrjournals.org Downloaded from electrophoretically on 7.5% SDS-polyacrylamide gels and transferred onto polyvinylidene difluoride membranes (Roche) according to previously published method (38) . The membrane was probed with an anti-SPHK1 rabbit antibody (1:1,000 dilution; Abgent). Expression of SPHK1 was determined with horseradish peroxidase-conjugated antirabbit immunoglobulin G 1:3,000 diluted and enhanced chemiluminescence (Pierce) according to the manufacturer's suggested protocol. The membranes were stripped and reprobed with an anti-h-actin mouse monoclonal antibody (1:1,000 dilution; Sigma) as a loading control.
Immunohistochemistry. Immunohistochemical analysis was done to study altered protein expression in 243 human astrocytoma tissues. The procedures were carried out similarly to previously described methods (38) . In brief, paraffin-embedded specimens were cut into 4 Am sections and baked at 65jC for 30 min. The sections were deparaffinized with xylenes and rehydrated. Sections were submerged into EDTA antigenic retrieval buffer and microwaved for antigenic retrieval. The sections were treated with 3% hydrogen peroxide in methanol to quench the endogenous peroxidase activity followed by incubation with 1% bovine serum albumin to block the nonspecific binding. Rabbit anti-SPHK1 (1:50 dilution; Abgent) was incubated with the sections overnight at 4jC. For negative controls, the primary antibody was replaced by normal goat serum. After washing, the tissue sections were treated with biotinylated anti-rabbit secondary antibody (Zymed) followed by a further incubation with streptavidin-horseradish peroxidase complex (Zymed). The tissue sections were immersed in 3-amino-9-ethyl carbazole and counterstained with 10% Mayer's hematoxylin, dehydrated, and mounted in Crystal Mount. The degree of immunostaining of formalin-fixed, paraffin-embedded sections was viewed and scored separately by two independent investigators, who were blinded to the histopathologic features and patient data of the samples, and the scores were determined by combining the proportion of positively stained tumor cells and the intensity of staining. Scores given by the two independent investigators were averaged for further comparative evaluation of the SPHK1 expression. The proportion of positively stained tumor cells was graded as follows: 0 (no positive tumor cells), 1 (<10% positive tumor cells), 2 (10-50% positive tumor cells). and 3 (>50% positive tumor cells). The cells at each intensity of staining were recorded on a scale of 0 (no staining), 1 (weak staining, light yellow), 2 (moderate staining, yellowish brown), and 3 (strong staining, brown). The staining index was calculated as follows: staining index = staining intensity Â proportion of positively stained tumor cells. Using this method of assessment, we evaluated the expression of SPHK1 in astrocytomas by staining index (scored as 0, 1, 2, 3, 4, 6, or 9). Cutoff values to define the high and low expression of SPHK1 were chosen based on a measure of heterogeneity with the log-rank test statistics with respect to overall survival. An optimal cutoff value was identified. The staining index score z 6 was used to define tumors with high expression, and staining index V 4 as tumors with low expression of SPHK1.
Immunohistochemical staining for protein expression in tumor and normal tissues was quantitatively analyzed with the AxioVision Rel.4.6 computerized image analysis system assisted with the automatic measurement program (Carl Zeiss). Briefly, the stained sections were evaluated at Â200 magnification, and 10 representative staining fields of each section were analyzed to verify the mean absorbance, which represents the strength of staining signals as measured per positive pixels. The mean absorbance data were statistically analyzed using t test Fig. 3 . Immunohistochemical analysis of SPHK1expression in normal brain tissue and primary astrocytomas. A, thin sections of paraffin-embedded specimens of a total of 4 normal brain tissues and 243 primary astrocytoma specimens including WHO grade 1to 4 astrocytoma samples were stained by immunohistochemistry using an anti-SPHK1antibody. a and b, normal brain tissue; c and d, WHO grade 1 pilocytic astrocytoma; e and f, WHO grade 2 diffuse astrocytoma; g and h, WHO grade 3 anaplastic astrocytomas; i and j, WHO grade 4 glioblastoma multiforme. Amplification, Â200 (a, c, e, g, and i) and Â400 (b, d, f, h and j). Immunohistochemical analyses were done two independent times on each of the samples with similar results. B, statistical quantification of the average mean absorbance of SPHK1staining between normal brain tissues (4 cases) and astrocytoma specimens of different WHO grades (30 random cases per grade). Average mean absorbance of SPHK1staining increases as astrocytoma progresses to higher grades. *, P < 0.01. to compare the average mean absorbance difference between different groups of tissues, and P < 0.05 was considered significant.
Statistical analysis. All statistical analyses were carried out using the SPSS 10.0 statistical software package. The m 2 test was used to analyze the relationship between SPHK1 expression and the clinicopathologic characteristics. Bivariate correlations between study variables were calculated by Spearman rank correlation coefficients. Survival curves were plotted by the Kaplan-Meier method and compared by the logrank test. Survival data were evaluated using univariate and multivariate Cox regression analyses. In all cases, P < 0.05 was considered statistically significant.
Results
Increased expression of SPHK1 in astrocytomas. Western blotting and RT-PCR analyses were done to determine the levels of SPHK1 protein and mRNA, respectively, in normal human astrocytes and astrocytoma cell lines U87MG, LN-235, LN-382, LN-444, LN-464, T98G, A172, and SNB19. Compared with normal human astrocytes, which showed no SPHK1 expression, all tumor cell lines expressed significantly higher levels of SPHK1 protein (Fig. 1A) and SPHK1 mRNA expression (Fig. 1B ).
To determine whether the level of SPHK1 is associated with the progression of astrocytoma, comparative analysis of SPHK1 expression was conducted on four pairs of matched astrocytoma tissue and the noncancerous tissue adjacent to the malignant lesion using Western blotting and RT-PCR analyses. As shown in Fig. 2A , the expression of SPHK1 protein was upregulated in all four human primary astrocytoma samples compared with their paired adjacent noncancerous tissue. Similarly, the mRNA expression level of SPHK1 was also upregulated in astrocytoma malignant lesions compared with that in the adjacent brain tissue (Fig. 2B) . Furthermore, the result of RT-PCR analysis showed that the tumor/normal ratio of SPHK1 message expression could be as high as 6.8-fold in one case of four paired primary astrocytoma tissues (Fig. 2C) . It is of note that the level of SPHK1 protein in the astrocytoma cell lines and clinical astrocytoma tissues was paralleled with the mRNA expression level, indicating the possibility that the increase of SPHK1 in astrocytoma might be largely attributable to regulation at the mRNA level ( Fig. 2B and D) .
Correlation between increased expression of SPHK1 and malignancy of astrocytomas. To determine whether the expression level of SPHK1 protein is associated with the histologic characteristics of astrocytomas, 243 paraffin-embedded, archived astrocytoma clinical specimens were examined, including 30 cases of grade 1, 77 cases of stage II, 86 cases of grade 2, and 50 cases of stage IV astrocytomas, by immunohistochemical staining with an antibody against human SPHK1. As shown in Fig. 3A , SPHK1 was found to be upregulated in astrocytomas (c and d, grade 1 astrocytomas; e and f, grade 2 astrocytomas; g and h, grade 3 astrocytomas; and i and j, grade 4 astrocytomas) compared with that in the normal brain tissue (Fig. 3) . As summarized in Table 1, SPHK1 protein was detected in 227 of 243 (93.4%) cases. High levels of SPHK1 were present in areas containing tumor cells in primary astrocytomas tumors (Fig. 3A, c-j) . In contrast, SPHK1 was hardly detectable in the normal brain tissue (Fig. 3A and B) . Quantitative analysis indicated that the average mean absorbance of SPHK1 staining in grades 1 to 4 tumors were statistically significantly higher than that in normal brain tissue (P < 0.01; Fig. 3B ).
We next analyzed the correlation between the expression of SPHK1 protein and the histologic staging of astrocytomas. On immunostaining examination on tumor sections obtained from 243 patients, positive SPHK1 expression was found to be strongly correlated with the clinicopathologic grades of the patients (P = 0.000), whereas it showed no difference among all ages (P = 0.1) or between genders (P = 0.443; Table 2 ). Spearman correlation analysis also revealed a correlation coefficient between SPHK1 expression level and the histologic grading of astrocytoma as 0.280 (P = 0.000; Table 3 ). Taken together, these observations support the notion that the progression of astrocytomas is associated with increased SPHK1 expression.
Association between SPHK1 expression and patient prognosis. Statistical analysis presented in Table 3 revealed an inverse correlation between SPHK1 level and the patient survival (P = 0.005). Spearman analysis also showed a correlation coefficient between SPHK1 and patient survival as 0.250 (P = 0.003; Table 3 ). Furthermore, log-rank test and KaplanMeier analysis were also applied to calculate the effect of SPHK1 expression and histologic staging of astrocytomas on Fig. 4 . Kaplan-Meier curves with univariate analyses (log-rank) for patients with low SPHK1-expressing (bold line) versus high SPHK1-expressing tumors (dotted line). The cumulative 3-year survival rate was 57.7% (95% confidence interval, 0.517-0.637) in the low SPHK1expression group (n = 143), whereas it was only 10.3% (95% confidence interval, 0.041-0.165) in the high SPHK1expression group (n = 100). Research.
on July 9, 2017. © 2008 American Association for Cancer clincancerres.aacrjournals.org Downloaded from survival in more details. The log-rank test showed that the expression level of SPHK1 protein in astrocytomas was significantly correlated with patients' survival time (P < 0.001) with a correlation coefficient of -0.433 ( Fig. 4A; Table 4 ). More specifically, the median survival time of patients whose tumors showed high expression levels of SPHK1 protein was only 18.00 months (95% confidence interval, 10.22-25.78), whereas the median survival time of those with low levels of SPHK1 expression was 40.00 months (95% confidence interval, 35.94-44.06). As shown in Fig. 4 , the cumulative 3-year survival rate was 57.7% (95% confidence interval, 0.517-0.637) in the low SPHK1 expression group (n = 143), whereas it was only 10.3% (95% confidence interval, 0.041-0.165) in the high SPHK1 expression group (n = 100). Multivariate survival analysis shown in Table 4 indicated that SPHK1 expression level was an independent prognostic factor for the assessment of patient outcomes.
We further examined the prognostic value of SPHK1 expression in different subgroups of astrocytoma patients stratified in relation to the histologic staging. Significant correlation between high SPHK1 expression and shorter overall survival time was found in WHO grading subgroups of astrocytomas. Patients with tumors exhibiting high SPHK1 expression had significantly shorter overall survival than those with low expression of SPHK1 in either grades 1 + 2 subgroup (n = 59; P = 0.038, log-rank; Fig. 5A ) or grades 3 + 4 subgroup (n = 76; P = 0.041, log-rank; Fig. 5B ), indicating that SPHK1 could be a valuable prognostic marker for astrocytoma patients at all disease stages.
Discussion
The key finding of our study is that the progression of human astrocytoma is associated with up-regulation of SPHK expression. Whereas a previous report has described a correlation between the expression of SPHK1 mRNA and the poor survival of patients with glioblastoma multiforme, the highest grade of astrocytoma according to the WHO grading criteria (33) , the present study represents the first demonstration that SPHK1 mRNA and protein are up-regulated in all grades of human astrocytomas and that the degree of SPHK1 up-regulation increases as astrocytoma progresses to higher grades.
Recently, compelling evidence has linked SPHK1 up-regulation to cancer development and progression (39, 40) , and the up-regulation of SPHK1 has been revealed in several types of solid tumors, including glioblastoma, intestinal adenoma, acute erythroleukemia, prostate cancer, and colon cancer (33 -37) . It was reported that the induction of SPHK1 expression could be mediated by various mechanisms. For example, numerous growth factors and oncogenes, including platelet-derived growth factor, epidermal growth factor, nerve growth factor, glial cell line-derived neurotrophic factor, BCR/ ABL, ETV6, and hypoxia-inducible factor-1a, were shown to upregulate SPHK1 through activation of the cis-acting elements in the SPHK1 promoter, such as the hypoxia-inducible factorresponsive elements, the SP1 motifs and AP-2 motifs, via multiple signaling pathways, including the mitogen-activated protein kinase pathway, the phosphoinositide 3-kinase pathway, and the Janus kinase 2 pathway (41 -48) . On the other hand, epigenetic mechanisms have also been found to mediate the up-regulation of SPHK1. Imamura et al. have reported that Khps1, an antisense transcript of SPHK1, induces demethylation of CG sites and methylation of non-CG sites within the differentially methylated region, thereby changing the SPHK1 expression patterns (49) . Increased expression of SPHK1 has been found to enhance the antiapoptotic ability of the MCF-7 breast cancer cells, increase cell proliferation, and promote estrogen-dependent tumorigenesis (29 -31) . Ectopic expression of SPHK1 could promote G 1 -S transition and stimulate cell growth, colony formation in soft agar, and tumor growth in immunodeficient mice (27, 33) . Overexpression of SPHK1 elevates the expression of cyclooxygenase-2 in colon cancer (37) . The above oncogenic features of SPHK1 have also been confirmed by small interfering RNA-mediated SPHK1 knockdown or by activity inhibition with a dominant-negative SPHK1 construct or with SPHK1 inhibitors (31, 50, 51) . All these findings suggest that SPHK1 might play important roles in cancer development and progression, which prompted us to ask whether it is also clinically associated with the progression of astrocytoma. To address this question, we did studies to Further analysis of the relationship between SPHK1 staining and the clinicopathologic characteristics of the patients has shown a significant correlation between SPHK1 expression and the histopathologic staging of astrocytomas, revealing increased SPHK1 levels in higher grades of the disease, supporting the hypotheses that SPHK1 might play a role in the progression of astrocytoma and that it might represent a biomarker that identifies subsets of astrocytoma patients with more aggressive disease. It is of particular note that patients with high SPHK1 expression had shorter survival time, with a cumulative 3-year survival rate of 10.3% (95% confidence interval, 0.041-0.165) in contrast to the 57.7% 3-year survival rate in the low SPHK1 expression group (95% confidence interval, 0.517-0.637), suggesting the possibility of using SPHK1 as a predictor for patient prognosis and survival.
In a more detailed survival study, univariate and multivariate analyses have shown that high expression of SPHK1 is a predictor of poor prognosis for astrocytomas patients. It is of note that there is a significant correlation between shorter overall survival times of patients and high SPHK1 expression in both the early histologic stage subgroup (grades 1 and 2) and the late histologic stage subgroup (grades 3 and 4), suggesting that SPHK1 may be a useful prognostic marker for all grades of astrocytomas.
Although several lines of evidence have suggested that SPHK1 might be involved in cancer development and progression, only few studies have linked SPHK1 to astrocytomas. Knockdown of SPHK1 has been found to decrease the proliferation rate of glioblastoma cell lines, prevent cells from exiting G 1 phase of the cell cycle, and slightly increase apoptosis (33) . Furthermore, Radeff-Huang et al. have reported that SPHKdependent AKT activation plays a significant role in tumor necrosis factor-a-induced cyclin D expression and cell proliferation (52). Despite the above findings, however, the precise pathway that SPHK1 might use to promote astrocytoma development and progression remains to be clarified. Based on the findings from our study and others, further investigation on whether SPHK1 can be used as a therapeutic target for novel antiastrocytoma approaches is warranted.
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